Mon. Nov 28th, 2022
Biocon#39;s partner Equillium gets USFDA nod to begin phase-3 trial of itolizumab on COVID-19 patients The Phase 3 trial called as EQUINOX will enroll a total of 800 patients at sites in the United States and abroad and include interim assessments at 20 percent and 50 percent of enrollment.